A clinical study of an oncolytic herpes simplex type 1 (HSV-1) G47delta for patients with castration resistant prostate cancer
- Conditions
- Castration resistant prostate cancer
- Registration Number
- JPRN-UMIN000010463
- Lead Sponsor
- The University of Tokyo Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 9
Not provided
-Administration of other clinical study drugs within 30 days of G47delta administration -Known HIV seropositivity -Current diagnosis of any medical or psychological condition that might interfere with the subject's ability to participate -Blood test results outside protocol specified limits -Evidence of active herpes infection -Current diagnosis of any active malignant tumor -Active uncontrolled infection that precludes surgery -History of alcohol or other drug abuse -Allergy to anti-HSV drug (acyclovir) -Administration of any anticancer drugs within 30 days of G47delta administration -Administration of any anti-androgen drugs within 30 days of G47delta administration -Conditions considered inadequate for the subject to be enrolled in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method